## Highlights of This Issue 339

### CHEMICAL THERAPEUTICS

341 | The HSP70 and Autophagy Inhibitor Pifithrin-\(\mu\) Enhances the Antitumor Effects of TRAIL on Human Pancreatic Cancer  
Hiroyuki Momma, Nanae Harashima, Touko Inao, Shinji Okano, Yoshitsugu Tajima, and Mamoru Harada

352 | Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner  
Anna R. McCarthy, Marijke C.C. Sachweh, Maureen Higgins, Johanna Campbell, Catherine J. Drummond, Ingeborg M.M. van Leeuwen, Lisa Pirrie, Marcus J.G.W. Ladds, Nicholas J. Westwood, and Sonia Lain  
See article, p. 471

361 | Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma  

373 | Novel Inhibitors of Rad6 Ubiquitin Conjugating Enzyme: Design, Synthesis, Identification, and Functional Characterization  
Matthew A. Sanders, Ghali Brahemi, Pratima Nangia-Makker, Vitaly Balan, Matteo Morelli, Hend Kothayer, Andrew D. Westwell, and Malathy P.V. Shekhar

### SMALL MOLECULE THERAPEUTICS

384 | HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo  
Megumi Kawamoto, Tomohisa Horibe, Masayuki Kohno, and Koji Kawakami

### LARGE MOLECULE THERAPEUTICS

394 | Targeting IGF-1R with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts  
Cale D. Fahrenholtz, Pedro J. Beltran, and Kerry L. Burnstein

405 | Poly(\(\beta\)-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo  
Chandrashekhar D. Kamat, Ron B. Shmueli, Nick Connis, Charles M. Rudin, Jordan J. Green, and Christine L. Hann

416 | A Human Single-Domain Antibody Elicits Potent Antitumor Activity byTargeting an Epitope in Mesothelin Close to the Cancer Cell Surface  
Zhewei Tang, Mingqian Feng, Wei Gao, Yen Phung, Weizao Chen, Amit Chaudhary, Brad St. Croix, Min Qian, Dimitri S. Dimitrov, and Mitchell Ho

427 | Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models  
Yaming Wu, Yixian Zhang, Maoliang Wang, Qi Li, Zhengxing Qu, Victoria Shi, Patricia Kraft, Steve Kim, Ying Gao, Jenny Pak, Stephen Youngster, Ivan D. Horak, and Lee M. Greenberger

### CANCER THERAPEUTICS INSIGHTS

438 | Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells  
Ruwanthi N. Gunawardane, Ronald R. Nepomuceno, Allison M. Rooks, Jeremy P. Hunt, Jill M. Ricono, Barbara Belli, and Robert C. Armstrong
ABOUT THE COVER

The yeast Rad6 human homologues HHR6A and HHR6B (or Rad6A and Rad6B) encode ubiquitin-conjugating enzymes (or E2) that play a central role in substrate ubiquitination and E3 ligase selection. The ubiquitin-conjugating activity of Rad6 is essential for its function in postreplication DNA repair, damage-induced mutagenesis, and proteolysis. Using virtual screening of ZINC database against a pharmacophore model for consensus, E2-ubiquitin binding sites followed by biological evaluation of virtual hits, two small molecule compounds with a triazine core structure, and possessing Rad6 ubiquitin conjugation inhibitory activity were identified. These small molecules inhibit breast cancer cell proliferation, migration, and colony formation by blocking G2–M progression. For details, see article by Sanders and colleagues on page 373.